Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis: A Short-term Clinical Study
-
- MOCHIZUKI Takeshi
- Department of Orthopedic Surgery, Kamagaya General Hospital
-
- 桃原 茂樹
- 鎌ヶ谷総合病院 整形外科
Bibliographic Information
- Other Title
-
- 関節リウマチにおけるアバタセプト治療の短期成績
- カンセツ リウマチ ニ オケル アバタセプト チリョウ ノ タンキ セイセキ
Search this article
Abstract
Objective: Abatacept is a selective T-cell co-stimulation modulator and is an effective new therapy for rheumatoid arthritis. This study evaluated the efficacy and safety of abatacept in patients with rheumatoid arthritis.<br>Methods: A total of 38 patients (17 naïve, 21 switching) began abatacept treatment with a dose of 500 or 750 mg according to body weight.<br>Results: At 24 weeks, the following response rates were observed for all patients, naive patients, and switching patients, respectively: good European League Against Rheumatism responses of 39.5%, 41.2%, and 38.1% were attained; remission rates in terms of DAS28 (erythrocyte sedimentation rate) were 26.3%, 41.2%, and 14.3%; and simplified disease activity index scores were 18.4%, 35.3%, and 4.8%. Mean changes in matrix metalloproteinase-3 (MMP-3) concentration were greater for good responders versus nonresponders (−121 versus −42.8 ng/ml). The incidence of serious infections was 2.6% (pneumonia).<br>Conclusion: In this study, abatacept significantly reduced disease activity in patients with rheumatoid arthritis. The measure of effectiveness was the change in MMP-3 concentration. Switching patients seemed to make better progress than naive patients did. Abatacept demonstrated clinically meaningful efficacy and acceptable safety.
Journal
-
- Japanese Journal of Joint Diseases
-
Japanese Journal of Joint Diseases 32 (1), 1-8, 2013
Japanese Society for Joint Diseases
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205314798976
-
- NII Article ID
- 130004567978
- 40019714783
-
- NII Book ID
- AA12318192
-
- ISSN
- 18849067
- 18832873
-
- NDL BIB ID
- 024712711
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
-
- Abstract License Flag
- Disallowed